CJC-1295 is a growth hormone-releasing hormone analogue, while ipamorelin is a growth hormone secretagogue that acts through the ghrelin receptor.
A product labeled CJC / IPA 10/10mg generally indicates 10mg of each peptide. However, CJC-1295 formulations may differ, including versions with or without DAC, so the exact compound identity should be verified.
The 10/10mg designation describes product quantities, not an established human dosage.
CJC / IPA 10/10mg for Laboratory Research
Scientists investigate CJC-1295 and ipamorelin to better understand growth hormone secretion and endocrine signaling pathways.
When evaluating CJC / IPA 10/10mg research peptide blends, laboratories should consider:
- Certificate of Analysis (COA): Request batch-specific identity and purity results.
- Blend composition: Verify the stated 10mg/10mg quantities.
- CJC-1295 formulation: Confirm whether the product contains CJC-1295 with DAC or a no-DAC analogue.
- Analytical testing: Review suitable HPLC and mass spectrometry results.
- Supplier transparency: Check batch traceability and handling information.
CJC / IPA 10/10mg Price and Availability
When researching CJC / IPA 10/10mg price, CJC-1295 Ipamorelin research suppliers, or CJC / IPA peptide blend specifications, compare quality documentation and verified composition rather than price alone.
For general product information, explore Certified-PEP. Specific pricing, availability, and testing documentation should be confirmed directly.
Choosing a CJC / IPA Research Supplier
For legitimate laboratory procurement, prioritize transparent labeling, independently verifiable analytical results, and compliance with applicable regulations.
Important: CJC-1295 and ipamorelin are not FDA-approved for human therapeutic use. Their safety and effectiveness, individually or as a combination, have not been established for routine medical treatment.